English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduErlanger Health System and Vanderbilt University Medical Center, on behalf of Vanderbilt-Ingram Cancer Center (VICC), have entered into an agreement to design a long-term collaboration in cancer care, including VICC hematology-oncology services at Erlanger’s two clinic and infusion locations.
Tag: Oncology
MSK Physician-Scientists Recognized with Top Honors by AACR, ASCO, and ASH Organizations
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.
Putting “Super” in Natural Killer Cells
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
Andre Goy, M.D., Appointed Physician-in-Chief to Lead Cancer Care Across Hackensack Meridian Health Network
“Thanks to Andre Goy’s leadership, John Theurer Cancer Center has flourished to become one of the nation’s leading cancer care and research centers, and that expertise now extends throughout our entire network,” noted Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. “With Dr. Goy at the helm as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service, patients and physicians throughout the state will benefit from his acumen and vision.”
Scientists Reveal How Mutations in Metabolism Can Drive Cancers
Yale Cancer Center scientists have identified mutations in metabolite-producing genes as a disruption of DNA repair. These mutation-driven “oncometabolites” may make cells more prone to developing cancer—but also more vulnerable to new cancer treatment strategies.
Bacteria in Cancer Cells May Help or Hinder Treatment
Weizmann Institute scientists show that bacteria live inside all cancer cells, from brain to breast to bone, and that each type of cancer has its own type of bacteria. Understanding this relationship could help predict treatment effectiveness or lead to ways of using the bacteria to boost treatments.
Study Shows Clinical Evidence of Anti-Tumor Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
At-home screening for ovarian, breast cancers is effective
At-home genetic-testing kits for breast and ovarian cancer risk are just as effective, and in some cases even more so, than the typical protocol for genetic testing, which requires repeated office visits and counseling, according to a study led by UW Medicine researchers.
Troublemaking ‘lesion’ singled out in UV-caused skin cancer
Upon exposure to human skin, ultraviolet light from the sun almost instantly generates two types of “lesions” that damage DNA. Scientists at UW Medicine in Seattle determined which of these lesions is responsible for activating a process that may increase cancerous mutations in cells.
Cancer Research Institute and IQVIA Uncover the Impact of COVID-19 Pandemic on Global Oncology Clinical Trials
New study reveals impact of COVID-19 pandemic on cancer clinical trials, published in Nature Reviews Drug Discovery
National Comprehensive Cancer Network Annual Conference Sessions Now Free Online
The NCCN 2020 Annual Conference (#NCCN2020) providing the latest updates on cancer treatment recommendations was initially postponed due to COVID-19. The CE-accredited sessions are now available as online webinars.
Study Demonstrates Impact of Both Inherited and Acquired Mutations on Cancer
The common belief that tumors arise via activation of a few genes that “drive” cancer development is unsupported by a widespread investigation into those genes and others in three large patient genetic databases, according to a study led by Yale Cancer Center (YCC) researchers.
Supportive Oncodermatology Interventions Improve Patient Quality of Life
A recent survey from the GW Cancer Center found that enrollment in a supportive oncodermatology program is associated with a significantly improved quality of life score. The results are published in the Journal of Drugs in Dermatology.
Schizophrenia drug combined with radiation shows promise in treating deadly brain tumors
UCLA researchers found that adding a drug once commonly used to treat schizophrenia to traditional radiation therapy helped improve overall survival in mice with glioblastoma, one of the deadliest and most difficult-to-treat brain tumors.
Moffitt Cancer Center Appoints John Cleveland as New Center Director
Moffitt Cancer Center Appoints John Cleveland as New Center Director
GW Dermatology Experts Available to Speak During Skin Cancer Awareness Month
WASHINGTON (April 28, 2020) — Skin cancer is one of the most common types of cancers, with 1 in 5 Americans developing it by the age of 70 and representing 1% of all cancer-related deaths according to the National Cancer…
Study Shows Immunotherapy Prior to Surgery May Help Destroy High-Risk Breast Cancer
A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
Uptake of Lung Cancer Screening May Depend on Making Testing Fast and Convenient
Value in Health announced today the publication of new research showing that uptake of lung cancer screening may depend on making testing fast and convenient.
Study points to obesity as driver of pancreatic cancer
A new study led by Yale Cancer Center (YCC) researchers has demonstrated in mice that hormones released from the pancreas itself can advance pancreatic cancer — and that weight loss can stop this process in its early stages. The research was published today in the journal Cell.
Genetics Researchers Find Easy Way to Improve Cancer Outcomes
By mining a vast trove of genetic data,researchers at the University of Virginia School of Medicine are enhancing doctors’ ability to treat cancer, predict patient outcomes and determine which treatments will work best for individual patients. The researchers have identified inherited variations in our genes that affect how well a patient will do after diagnosis and during treatment.
New blood test can detect wide range of cancers, now available to at risk individuals in clinical study at Dana-Farber
In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute and the Mayo Clinic.
Breast Cancer Screening Costs High, Benefits Uncertain, for Women in 40s
There are substantial costs associated with breast cancer screenings for U.S. women in their 40s, a new Yale Cancer Center-led study finds, and these costs vary widely by region.
Dr. Mehra Golshan Appointed Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center
Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.
OncoMX Knowledgebase Enables Research of Cancer Biomarkers and Related Evidence
Researchers at the George Washington University published a new knowledgebase and web portal, OncoMX, which will improve the exploration and research of cancer biomarkers in the context of related evidence.
NCCN 2020 Annual Conference to Examine Advances in Cancer Care and Emerging Issues in Oncology
Cancer care providers will gather in Orlando on March 20-22 for the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference: Celebrating 25 Years of NCCN. The three-day, in-person conference features more than 30 educational sessions on state-of-the-art practices in cancer care.
Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).
Wills Eye Hospital Announces Clinician-Scientist Jose S. Pulido, MD, MS, MBA, MPH to Hold Prestigious Endowed Chair
Wills Eye Hospital is pleased to announce Jose S. Pulido, MD, MS, MBA, MPH, a world-renowned retina and ocular oncology clinician-scientist, has been named the Larry A. Donoso Endowed Chair and Director of the Henry and Corrine Bower Memorial Laboratories for Translational Medicine, the Vickie and Jack Farber Vision Research Center at Wills Eye.
New Graphic Tobacco Warnings and the First Amendment
SUMMARYIn an article for JAMA Oncology, Tony Yang, a professor of health services and policy researcher at the George Washington University, and his co-authors at the Ohio State University argue that if the U.S. Food and Drug Administration’s 2019 proposed…
A New Outline of Cancer Therapies for Patients
Professor Yuval Shaked, head of the Technion Integrated Cancer Center, presents an outline for therapy that will prevent the development of cancer treatment resistance, with suggestions about how the information can be used clinically.
Lenox receives Yale Cancer Center Ruth McCorkle Oncology Advanced Practice Provider award
Raymond Lenox, APRN, was presented with the Yale Cancer Center Ruth McCorkle Oncology Advanced Practice Provider Award at YCC’s annual Conclave.
Yan wins Yale Cancer Center Class of 1961 Cancer Research Award
Qin Yan, Ph.D., was presented with the Yale Cancer Center (YCC) Class of 1961 Cancer Research Award at YCC’s annual Conclave
Yale Cancer Center presents Research awards during annual Conclave
Yale Cancer Center (YCC) held its annual Conclave and award ceremony. The night celebrated the accomplishments of goals set for 2019 and honored faculty and staff with clinical and research prizes.
Yale Cancer Center Awards for Clinical Excellence presented during annual Conclave
Debra Brandt, D.O. and Kevin Kim, M.D. were each honored with the Yale Cancer Center (YCC) Award for Clinical Excellence at YCC’s annual Conclave on Monday, January 13.
GW Cancer Center Expands Clinical Trial Offerings for Patients with High Risk Cutaneous Squamous Cell Carcinoma
The Cutaneous Oncology Program at the GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study, sponsored by Regeneron, will examine outcomes for patients treated with Libtayo® (cemiplimab) — an immunotherapy treatment — prior to surgery and radiation therapy.
Virtual Reality and Breast Cancer, First Italian-American Study Shows Promising Results
Virtual Reality during chemotherapy shown to improve breast cancer patients’ quality of life during the most stressful treatments, according to a recent study.
Virtual Reality and Breast Cancer, First Italian-American Study Shows Promising Results
Virtual Reality during chemotherapy shown to improve breast cancer patients’ quality of life during the most stressful treatments, according to a recent study.
Sanft named Chief Patient Experience Officer at Smilow Cancer Hospital
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
Mougalian appointed Deputy Chief Ambulatory Officer at Smilow Cancer Hospital
Sarah Mougalian, M.D., assistant professor of Medicine (Medical Oncology) has been named the inaugural Deputy Chief Ambulatory Officer at Smilow Cancer Hospital (SCH) at Yale New Haven Hospital.
Yale Cancer Center launches Center for Community Engagement and Health Equity
Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.
Bonni Lee Guerin, MD Honored By American Cancer Society – Northeast Region
Bonni Lee Guerin, MD, hematologist/oncologist and physician researcher at Overlook Medical Center, was honored by the American Cancer Society for her role in advancing breast cancer treatment and prevention. In addition to her forward-looking clinical approach, Dr. Guerin is the principal investigator (PI) of numerous clinical trials exploring new ways to incorporate the latest advances in the management of breast cancer. Dr. Guerin was PI at Atlantic Health System, with the largest number of study participants of any center in the New York-New Jersey metro area, for the landmark TAILORx clinical trial.
Managing the Holidays with a Long-Term Illness
Leora Lowenthal, LICSW-OSW-C, manager of the oncology social work program at BIDMC, and Hester Hill Schnipper, LICSW, OSW-C, provide advice on rethinking holiday traditions and celebrations to capture more peace in the face of a long-term illness.
Clinical Research Pathways Partners with WellStar Health System to Increase Diversity in Clinical Trials
Clinical Research Pathways, an Atlanta-based non-profit, announces a grant to Wellstar Health System designed to increase diversity in oncology-related clinical trials
Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers
In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer
Yale Cancer Center study highlights challenges for care of AML patients during initial chemotherapy
A new study by Yale Cancer Center (YCC) researchers shows understanding treatment patterns for patients with acute myeloid leukemia (AML) is vital to develop strategies to improve outcomes.
Yale Cancer Center researchers show identifying type of chronic pain in adults with sickle cell disease may lead to better outcomes
Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.
Human Immune Monitoring Center at Mount Sinai to analyze the effectiveness of a novel cancer therapy drug
The Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo® (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.
Marker reveals if benign-appearing meningiomas are perilous
A modified protein in benign-appearing meningiomas can reveal which are truly benign and which are more dangerous and require more aggressive treatment, researchers have discovered.
Smilow Cancer Hospital expert explains five things you need to know about Lung Cancer
Roy Herbst, M.D., Ph.D., chief of Medical Oncology at Smilow Cancer Hospital, has been researching lung cancer and treating patients with the disease for more than 25 years. He discusses the facts about lung cancer, ways to reduce your risk, and how new treatments are significantly extending life for patients.
Yale Cancer Center study shows checkpoint inhibitor prolongs survival in patients with certain head and neck cancers
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC).